Showing 4 posts of 4 posts found.


Eisai withdraws weight loss drug Belviq after FDA highlights cancer risk

February 14, 2020
Medical Communications, Research and Development, Sales and Marketing Belviq, Eisai, FDA, pharma

The FDA has requested that Eisai withdraw its weight loss drug Belviq (lorcaserin) and Belviq XR from the US market …

Victoza image

FDA panel backs liraglutide for obesity

September 12, 2014
Manufacturing and Production, Sales and Marketing Arena Pharmaceuticals, Belviq, Novo Nordisk, Qsymia, Victoza, Vivus, diabetes, obesity

An FDA panel has voted 14-1 to allow a form of Novo Nordisk’s type 2 diabetes treatment Victoza to help …

FDA image

FDA clears Arena and Eisai’s obesity drug

June 28, 2012
Sales and Marketing Arena, Belviq, Eisai, FDA, Qnexa, Roche, obesity

Eisai and Arena’s Belviq has gained FDA approval, making it the first obesity drug to be approved in over ten …

Latest content